OBJECTIVES: Clinical guidelines are available at national level for the treatment of patients with psoriatic arthritis (PsA) in the Brazilian public health system (SUS). The present research aims to estimate the budget impact of the incorporation of golimumab (GOL) as an additional biological drug (biological) in these guidelines. METHODS: A budget impact analysis (BIA) was developed using a three health states Markov model (new/first line, second line and discontinued) with annual cycle length. The budget impact of GOL incorporation was compared to the current scenario, from SUS perspective. Target population was patients either naïve to biological or receiving the first biological, estimated based on DATASUS database. A 5-year time horizon was employed and GOL adoption rate was assumed as 40% in naïve patients at the end of 5 years and 33,3% of patients switching the first biological. Patients discontinuing the second biological remained in ‘discontinued state’ until the end of the analysis. Only drug acquisition costs were considered and prices were gathered from the official government website. Annual treatment costs were calculated following doses/intervals defined in the guidelines. Deterministic sensitivity analysis (DSA) was carried to determine the impact of the assumptions on results. RESULTS: